Skip to main content
Erschienen in: Medical Oncology 7/2014

01.07.2014 | Original Paper

Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review

verfasst von: Jian Zhang, Linlin Ma, Zelin Xie, Yuwen Guo, Wen Sun, Lei Zhang, Jun Lin, Jing Xiao, Yichen Zhu, Ye Tian

Erschienen in: Medical Oncology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

This study investigated the incidence and types of post-transplant malignancy in Chinese renal transplant recipients and the risk factors associated with malignancy. Data from 3,462 patients who underwent renal transplantation at Beijing Friendship Hospital were combined with data from 26 previous reports describing malignancy rates in 27,170 Chinese renal transplant recipients. Between 1974 and 2014, 179/3,462 (5.17 %) patients who underwent renal transplantation at our center developed malignancy. The most common site of malignancy was the urinary system, and the most common type was urothelial transitional cell carcinoma. Combined data from our center and previous reports showed malignancy in 671 (2.19 %) Chinese renal transplant recipients. The ten most common malignancies were urothelial transitional cell carcinoma (n = 283), hepatocellular carcinoma (n = 68), gastrointestinal cancer (n = 63), renal cell carcinoma (n = 42), lymphoma (n = 42), lung cancer (n = 28), breast cancer (n = 19), skin cancer (n = 18), Kaposi’s sarcoma (n = 12), and cervical cancer (n = 10). The incidence of post-transplant malignancy in renal transplant recipients was lower in China than the reported rates in other countries, and the most common sites of malignancy were the urinary and digestive system. The relative frequency of malignancy sites differed between northern and southern China. Renal transplant recipients on long-term immunosuppressive therapy should receive careful follow-up, including annual or biannual screening for malignancy in high-risk individuals.
Literatur
1.
Zurück zum Zitat Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227–43.PubMedCrossRef Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227–43.PubMedCrossRef
2.
Zurück zum Zitat Navarro MD, López-Andréu M, Rodríguez-Benot A, Agüera ML, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transplant Proc. 2008;40(9):2936–40.PubMedCrossRef Navarro MD, López-Andréu M, Rodríguez-Benot A, Agüera ML, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transplant Proc. 2008;40(9):2936–40.PubMedCrossRef
3.
Zurück zum Zitat Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant. 2011;16(2):14–8.PubMed Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant. 2011;16(2):14–8.PubMed
4.
Zurück zum Zitat Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, Sharif A. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2013. doi:10.1038/ki.2013.458.PubMed Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, Sharif A. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2013. doi:10.​1038/​ki.​2013.​458.PubMed
5.
Zurück zum Zitat Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG. Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009;31(3):288–91 (in Chinese).PubMed Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG. Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009;31(3):288–91 (in Chinese).PubMed
6.
Zurück zum Zitat Cao WJ, Liu ZZ, Li JX. Clinical analysis of malignant tumors after kidney transplantation. Chin Mod Med. 2012;19(2):22–4 (in Chinese). Cao WJ, Liu ZZ, Li JX. Clinical analysis of malignant tumors after kidney transplantation. Chin Mod Med. 2012;19(2):22–4 (in Chinese).
7.
Zurück zum Zitat Fan Y, Tan MY. Clinical experience in treatment of malignant tumors after kidney transplantation. Chin J Org Transplant. 2009;30(1):34–6 (in Chinese). Fan Y, Tan MY. Clinical experience in treatment of malignant tumors after kidney transplantation. Chin J Org Transplant. 2009;30(1):34–6 (in Chinese).
8.
Zurück zum Zitat Xu ZQ, Xu HY. Malignancy after renal transplantation: report of 4 cases. J Clin Urol. 2002;17(1):46 (in Chinese). Xu ZQ, Xu HY. Malignancy after renal transplantation: report of 4 cases. J Clin Urol. 2002;17(1):46 (in Chinese).
9.
Zurück zum Zitat Long W, Yang GT, Jiang W, Liu YB, Pei XK, Bai YM. Sixteen cases of malignant tumor after renal transplantation: clinical report and literature review. Chin J Tissue Eng Res. 2012;16(40):7450–4 (in Chinese). Long W, Yang GT, Jiang W, Liu YB, Pei XK, Bai YM. Sixteen cases of malignant tumor after renal transplantation: clinical report and literature review. Chin J Tissue Eng Res. 2012;16(40):7450–4 (in Chinese).
10.
Zurück zum Zitat Chen GY, Yao XP, Chen YY, Jiang JG. Clinical study of malignancy in renal allograft recipients. J Clin Urol. 2003;18(3):144–5 (in Chinese). Chen GY, Yao XP, Chen YY, Jiang JG. Clinical study of malignancy in renal allograft recipients. J Clin Urol. 2003;18(3):144–5 (in Chinese).
11.
Zurück zum Zitat Xu XM, Zhang Y, Xu ZQ, Zheng SL, Yang YR, Xia P. Profiles of malignant tumors following kidney transplantation: an analysis of 34 cases. Chin J Transplant (Electronic Edition). 2012;6(2):97–104 (in Chinese). Xu XM, Zhang Y, Xu ZQ, Zheng SL, Yang YR, Xia P. Profiles of malignant tumors following kidney transplantation: an analysis of 34 cases. Chin J Transplant (Electronic Edition). 2012;6(2):97–104 (in Chinese).
12.
Zurück zum Zitat Hu XP, Ma LL, Zhang XD, Chen X, Wang W, Li XB, Wang Y. Clinical analysis of malignant tumor following renal transplantation. J Clin Surg. 2006;14(8):504–5 (in Chinese). Hu XP, Ma LL, Zhang XD, Chen X, Wang W, Li XB, Wang Y. Clinical analysis of malignant tumor following renal transplantation. J Clin Surg. 2006;14(8):504–5 (in Chinese).
13.
Zurück zum Zitat Niu B, Lin J, Chen XY, Li YC. Clinical analysis of de novo malignancies after renal transplantation. Org Transplant. 2013;4(2):91–4 (in Chinese). Niu B, Lin J, Chen XY, Li YC. Clinical analysis of de novo malignancies after renal transplantation. Org Transplant. 2013;4(2):91–4 (in Chinese).
14.
Zurück zum Zitat Hao JW, Song H, Chang Z, Lin CS, Zhang AM, Li XT. Clinical study of 39 patients with malignant tumor after renal transplantation. Cancer Res Clin. 2012;24(1):38–40 (in Chinese). Hao JW, Song H, Chang Z, Lin CS, Zhang AM, Li XT. Clinical study of 39 patients with malignant tumor after renal transplantation. Cancer Res Clin. 2012;24(1):38–40 (in Chinese).
15.
Zurück zum Zitat Zheng QY, Yang L, Hua X, Luo YB. Clinical analysis of malignant tumor after renal transplantation. J Pract Med. 2010;26(13):2365–7 (in Chinese). Zheng QY, Yang L, Hua X, Luo YB. Clinical analysis of malignant tumor after renal transplantation. J Pract Med. 2010;26(13):2365–7 (in Chinese).
16.
Zurück zum Zitat Ma P, Sun XQ, Chen JC, Wen RM. Malignancy after renal transplantation: report of 3 cases. Acta Acad Med Xuzhou. 2003;23(1):77–8 (in Chinese). Ma P, Sun XQ, Chen JC, Wen RM. Malignancy after renal transplantation: report of 3 cases. Acta Acad Med Xuzhou. 2003;23(1):77–8 (in Chinese).
17.
Zurück zum Zitat Yu LX, Miao Y, Deng WF, Du YJ, Yu J, Fu SJ, Xu J, Du CF, Wang YB, Ye GR, Hu P. De novo cancers in kidney transplant recipients. Chin J Org Transplant. 2010;31(5):265–8 (in Chinese). Yu LX, Miao Y, Deng WF, Du YJ, Yu J, Fu SJ, Xu J, Du CF, Wang YB, Ye GR, Hu P. De novo cancers in kidney transplant recipients. Chin J Org Transplant. 2010;31(5):265–8 (in Chinese).
18.
Zurück zum Zitat Fan Y, Shi BY, Chang JY, Bo HW, Wang Z, Ou YY, Du Y, Qian YY. Analysis on the occurrence of malignant tumors after kidney transplantation. Med J Chin PLA. 2007;32(5):529–30 (in Chinese). Fan Y, Shi BY, Chang JY, Bo HW, Wang Z, Ou YY, Du Y, Qian YY. Analysis on the occurrence of malignant tumors after kidney transplantation. Med J Chin PLA. 2007;32(5):529–30 (in Chinese).
19.
Zurück zum Zitat Lin Z, Zhang JF, Chen J, Shao YQ, Zhang YB, Tong L, Hu ZX, Dong SF. Malignancy following renal transplantation: an analysis of 6 cases. Chin J Org Transplant. 2004;25(4):250 (in Chinese). Lin Z, Zhang JF, Chen J, Shao YQ, Zhang YB, Tong L, Hu ZX, Dong SF. Malignancy following renal transplantation: an analysis of 6 cases. Chin J Org Transplant. 2004;25(4):250 (in Chinese).
20.
Zurück zum Zitat Dong J, Ao JH, Xiao XR, Ye LY, Hong BF, Wang XX, Li YT. Malignancies following renal transplantation: A report of 19 cases. Chin J Org Transplant. 2001;22(4):214–5 (in Chinese). Dong J, Ao JH, Xiao XR, Ye LY, Hong BF, Wang XX, Li YT. Malignancies following renal transplantation: A report of 19 cases. Chin J Org Transplant. 2001;22(4):214–5 (in Chinese).
21.
Zurück zum Zitat Zhao XH, Guo QX, Qin F. Clinical analysis of 14 patients with malignancy after renal transplantation. J Zhengzhou Univ (Medical Sciences). 2004;39(4):731 (in Chinese). Zhao XH, Guo QX, Qin F. Clinical analysis of 14 patients with malignancy after renal transplantation. J Zhengzhou Univ (Medical Sciences). 2004;39(4):731 (in Chinese).
22.
Zurück zum Zitat Qu LH, Li Q, Chen JH, Wu JY, Wang YM, Zhang JG, Wang SY, Huang HF, He Q. Clinical analysis of malignant tumors in recipients of renal transplantation. Chin J Urol. 2004;25(7):445–7 (in Chinese). Qu LH, Li Q, Chen JH, Wu JY, Wang YM, Zhang JG, Wang SY, Huang HF, He Q. Clinical analysis of malignant tumors in recipients of renal transplantation. Chin J Urol. 2004;25(7):445–7 (in Chinese).
23.
Zurück zum Zitat Yang HW, Xiang J, Liu L, Wu QS, Duan WL. Malignancy following renal transplantation: report of 17 cases. Shenyang Bu Dui Yi Yao. 2003;16(6):527 (in Chinese). Yang HW, Xiang J, Liu L, Wu QS, Duan WL. Malignancy following renal transplantation: report of 17 cases. Shenyang Bu Dui Yi Yao. 2003;16(6):527 (in Chinese).
24.
Zurück zum Zitat Tian XJ, Ma LL, Wang GL, Hou XF, Luo KP, Zhao L. Malignancies in renal transplant recipients: a report of 6 cases. J Clin Urol. 2005;20(1):49–50 (in Chinese). Tian XJ, Ma LL, Wang GL, Hou XF, Luo KP, Zhao L. Malignancies in renal transplant recipients: a report of 6 cases. J Clin Urol. 2005;20(1):49–50 (in Chinese).
25.
Zurück zum Zitat Lin RX, Yang SL, Wu WZ, Lin WH. Malignant tumor following renal transplantation. Chin J Org Transplant. 2003;24(3):139–40 (in Chinese). Lin RX, Yang SL, Wu WZ, Lin WH. Malignant tumor following renal transplantation. Chin J Org Transplant. 2003;24(3):139–40 (in Chinese).
26.
Zurück zum Zitat Fei JG, Chen LZ, Zhao JQ, Wang CX, Qiu J, Deng SX, Li J, Chen GD. Analysis on the risk factors and prognosis of malignant tumor in kidney transplantation recipients. Chin J Org Transplant. 2008;29(10):617–9 (in Chinese). Fei JG, Chen LZ, Zhao JQ, Wang CX, Qiu J, Deng SX, Li J, Chen GD. Analysis on the risk factors and prognosis of malignant tumor in kidney transplantation recipients. Chin J Org Transplant. 2008;29(10):617–9 (in Chinese).
27.
Zurück zum Zitat Dong CB, Zhu YH, Zhou MS, Wang YW, Min ZL. Analysis of malignant tumor following renal transplantation. J Clin Urol. 2004;19(2):67–8 (in Chinese). Dong CB, Zhu YH, Zhou MS, Wang YW, Min ZL. Analysis of malignant tumor following renal transplantation. J Clin Urol. 2004;19(2):67–8 (in Chinese).
28.
Zurück zum Zitat Yu X, Xu DL, Bo JM, Liu M, Lu P, Lv Q, Zhang W, Gu M. Clinical analysis of 15 patients with malignancy following renal transplantation. Acta Univ Med Nanjing (Nat Sci). 2010;30(9):1330–2 (in Chinese). Yu X, Xu DL, Bo JM, Liu M, Lu P, Lv Q, Zhang W, Gu M. Clinical analysis of 15 patients with malignancy following renal transplantation. Acta Univ Med Nanjing (Nat Sci). 2010;30(9):1330–2 (in Chinese).
29.
Zurück zum Zitat Wang HM, Gao CJ. Clinical analysis of malignancy in renal transplant recipients. Chin J Coal Indus Med. 2005;8(1):71–2 (in Chinese). Wang HM, Gao CJ. Clinical analysis of malignancy in renal transplant recipients. Chin J Coal Indus Med. 2005;8(1):71–2 (in Chinese).
30.
Zurück zum Zitat Xu RF, He XZ, Chao ZF, Che WJ, Jing H. Malignancy after renal transplantation: report of 6 cases. J Mod Urol. 2004;9(1):45–6. Xu RF, He XZ, Chao ZF, Che WJ, Jing H. Malignancy after renal transplantation: report of 6 cases. J Mod Urol. 2004;9(1):45–6.
31.
32.
Zurück zum Zitat Vasudev B, Hariharan S. Cancer after renal transplantation. Curr Opin Nephrol Hypertens. 2007;16(6):523–8.PubMedCrossRef Vasudev B, Hariharan S. Cancer after renal transplantation. Curr Opin Nephrol Hypertens. 2007;16(6):523–8.PubMedCrossRef
33.
Zurück zum Zitat Haberal AN, Süren D, Demirhan B, Bilezikçi B, Celasun B, Haberal M. Evaluation of post transplantation malignancies compared with de novo tumors. Transplant Proc. 2007;39(4):1057–62.PubMedCrossRef Haberal AN, Süren D, Demirhan B, Bilezikçi B, Celasun B, Haberal M. Evaluation of post transplantation malignancies compared with de novo tumors. Transplant Proc. 2007;39(4):1057–62.PubMedCrossRef
34.
Zurück zum Zitat Baccarani U, Adani GL, Montanaro D, Risaliti A, Lorenzin D, Avellini C, Tulissi P, Groppuzzo M, Currò G, Luvisetto F, Beltrami A, Bresadola V, Viale PL, Bresadola F. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc. 2006;38(4):1135–7.PubMedCrossRef Baccarani U, Adani GL, Montanaro D, Risaliti A, Lorenzin D, Avellini C, Tulissi P, Groppuzzo M, Currò G, Luvisetto F, Beltrami A, Bresadola V, Viale PL, Bresadola F. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc. 2006;38(4):1135–7.PubMedCrossRef
35.
Zurück zum Zitat Sheil AG, Disney AP, Mathew TG, Amiss N, Excell L. Malignancy following renal transplantation. Transplant Proc. 1992;24(5):1946–7.PubMed Sheil AG, Disney AP, Mathew TG, Amiss N, Excell L. Malignancy following renal transplantation. Transplant Proc. 1992;24(5):1946–7.PubMed
36.
Zurück zum Zitat Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000;7(2):147–56.PubMed Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000;7(2):147–56.PubMed
37.
Zurück zum Zitat Chen WQ, Zheng RS, Zhang SW, Zhao P, Zeng HM, Zou XN, He J. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26(1):48–58.PubMedCentralPubMed Chen WQ, Zheng RS, Zhang SW, Zhao P, Zeng HM, Zou XN, He J. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26(1):48–58.PubMedCentralPubMed
38.
Zurück zum Zitat Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.PubMedCrossRef Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.PubMedCrossRef
39.
Zurück zum Zitat Végso G, Tóth M, Hídvégi M, Toronyi E, Langer RM, Dinya E, Tóth A, Perner F, Járay J. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007;13(1):63–9.PubMedCrossRef Végso G, Tóth M, Hídvégi M, Toronyi E, Langer RM, Dinya E, Tóth A, Perner F, Járay J. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007;13(1):63–9.PubMedCrossRef
40.
Zurück zum Zitat Stratta P, Morellini V, Musetti C, Turello E, Palmieri D, Lazzarich E, Cena T, Magnani C. Malignancy after kidney transplantation: results of 400 patients from a single center. Clin Transplant. 2008;22(4):424–7.PubMedCrossRef Stratta P, Morellini V, Musetti C, Turello E, Palmieri D, Lazzarich E, Cena T, Magnani C. Malignancy after kidney transplantation: results of 400 patients from a single center. Clin Transplant. 2008;22(4):424–7.PubMedCrossRef
41.
Zurück zum Zitat Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7.PubMedCentralPubMedCrossRef Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7.PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transplant Int. 2000;13(suppl 1):S394–8.CrossRef Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transplant Int. 2000;13(suppl 1):S394–8.CrossRef
43.
Zurück zum Zitat Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941–8.PubMedCrossRef Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941–8.PubMedCrossRef
44.
Zurück zum Zitat Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.PubMedCrossRef Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.PubMedCrossRef
45.
Zurück zum Zitat Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, Ichikawa Y, Kurihara K, Imanishi M, Matsuno T, Aozasa K. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–20.PubMedCrossRef Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, Ichikawa Y, Kurihara K, Imanishi M, Matsuno T, Aozasa K. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–20.PubMedCrossRef
46.
Zurück zum Zitat Shin M, Moon HH, Kim JM, Park JB, Kwon CH, Kim SJ, Joh JW. Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center. Transplant Proc. 2013;45(8):3019–23.PubMedCrossRef Shin M, Moon HH, Kim JM, Park JB, Kwon CH, Kim SJ, Joh JW. Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center. Transplant Proc. 2013;45(8):3019–23.PubMedCrossRef
47.
Zurück zum Zitat Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102(3):179–86.PubMedCentralPubMedCrossRef Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102(3):179–86.PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Zhou L, Cao YL, Li WG, Fu FT, Zhang L, Wang X, Shi XH. Transitional cell carcinoma associated with aristolochic acid nephropathy: most common cancer in chronic hemodialysis patients in China. Chin Med J (Engl). 2012;125(24):4460–5. Zhou L, Cao YL, Li WG, Fu FT, Zhang L, Wang X, Shi XH. Transitional cell carcinoma associated with aristolochic acid nephropathy: most common cancer in chronic hemodialysis patients in China. Chin Med J (Engl). 2012;125(24):4460–5.
49.
Zurück zum Zitat Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14–20.PubMedCrossRef Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14–20.PubMedCrossRef
50.
Zurück zum Zitat Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation. 2008;86(6):784–90.PubMedCentralPubMedCrossRef Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation. 2008;86(6):784–90.PubMedCentralPubMedCrossRef
51.
Zurück zum Zitat Cheung CY, Lam MF, Chow KM, Lee W, Cheng YL, Yuen SK, Wong PN, Mo KL, Leung KT, Wong SH, Ho YW, Chau KF. Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong renal registry. Ren Fail. 2014. doi:10.3109/0886022X.2014.899879.PubMed Cheung CY, Lam MF, Chow KM, Lee W, Cheng YL, Yuen SK, Wong PN, Mo KL, Leung KT, Wong SH, Ho YW, Chau KF. Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong renal registry. Ren Fail. 2014. doi:10.​3109/​0886022X.​2014.​899879.PubMed
52.
Zurück zum Zitat Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007;96(7):1127–34.PubMedCentralPubMedCrossRef Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007;96(7):1127–34.PubMedCentralPubMedCrossRef
53.
Zurück zum Zitat Huang ZJ, Zhou MG, Wang LJ. Study on the geographic distribution of liver cancer mortality and HBsAg carrier rate in China (Article in Chinese). Dis Surv. 2007;22(4):242–5. Huang ZJ, Zhou MG, Wang LJ. Study on the geographic distribution of liver cancer mortality and HBsAg carrier rate in China (Article in Chinese). Dis Surv. 2007;22(4):242–5.
54.
Zurück zum Zitat Ishioka J, Saito K, Kijima T, Nakanishi Y, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Sakura M, Yonese J, Morimoto S, Noro A, Tsujiil T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2014. doi:10.1111/bju.12707.PubMed Ishioka J, Saito K, Kijima T, Nakanishi Y, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Sakura M, Yonese J, Morimoto S, Noro A, Tsujiil T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2014. doi:10.​1111/​bju.​12707.PubMed
55.
Zurück zum Zitat Kim B, Choi HJ, Kim MH, Cho KS. Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiol. 2012;53(8):943–9.PubMedCrossRef Kim B, Choi HJ, Kim MH, Cho KS. Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiol. 2012;53(8):943–9.PubMedCrossRef
Metadaten
Titel
Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review
verfasst von
Jian Zhang
Linlin Ma
Zelin Xie
Yuwen Guo
Wen Sun
Lei Zhang
Jun Lin
Jing Xiao
Yichen Zhu
Ye Tian
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 7/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0032-6

Weitere Artikel der Ausgabe 7/2014

Medical Oncology 7/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.